News

First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment.    Study Supports Potential Broad Utilization of Cytisinicline for Treatment of Nicotine Dependence.  Management to host conference call today, April 20, 2023 at 8:30AM EDT.  SEATTLE and VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq:…

SEATTLE, Wash. and VANCOUVER, British Columbia, April 14, 2023 – (GLOBE NEWSWIRE) Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes to the Company’s Board of Directors to continue to support the future direction of the Company. As…

Topline Data Expected in 2Q 2023. SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 17, 2023 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of…